Nipro Of Japan To Begin Marketing Human iPS Cells To Drug Makers
This article was originally published in PharmAsia News
Executive SummaryJapan's Nipro says it plans to launch soon the nation's first sale of cultivated human stem cells to drug makers and research institutes. Nipro said sales should begin in June of cardiac muscle cells developed from human induced pluripotent stem cells. Similar cells from iPS cells in monkeys already are available on the market, but Nipro expects the human samples to enable assessments of drug side effects more readily, improving the speed and efficacy of clinical tests. The cells to be marketed as kits were produced by ReproCell, a Japanese biotech venture. (Click here for more - a subscription may be required
You may also be interested in...
The Chinese government's plan to reduce tariffs it imposed on a slew of US exports is expected to have minimal impact on the overall medtech industry. See what Ralph Ives, AdvaMed's executive VP for global strategy, said about it here.
FDA approved sNDAs from GlaxoSmithKline for diclofenac-containing Voltaren Arthritis Pain for the temporary relief of arthritis pain and from Alcon for Pataday olopatadine drops at 0.2% concentration for once-daily use temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair or dander and 0.1% for twice-daily use for the same indications plus redness relief.